Compare Amgen, Inc. (AMGN) vs Burlington Stores Inc (BURL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Burlington Stores Inc — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Burlington Stores Inc trades at $326.88 (market cap $20.63B). The key difference: Amgen, Inc. is far larger — about 9.5× Burlington Stores Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| AMGN | BURL | |
|---|---|---|
Market Cap | $196.12B | $20.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $347.82 |
52-Week Low | $271.18 | $242.43 |
Enterprise Value | $241.41B | $25.75B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Burlington Stores (BURL) trades at $327.72, up 1.95% today, with strong technical momentum and consistent earnings beats. The stock shows bullish moving averages and is near its 52-week high. Recent quarters have exceeded EPS expectations, with Q1 2026 actual EPS of $2.01 beating the $1.80 estimate. Financials reveal robust revenue growth, with 2025 revenue at $10.63B and net income of $503.64M, while analyst sentiment remains overwhelmingly positive with 94% buy ratings.
BURL's outlook is favorable, driven by margin expansion and store productivity gains, but risks include high valuation multiples and competitive retail pressures. The consensus price target of $364.40 suggests upside potential, though investors should monitor debt levels and consumer spending trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
